← All reports

The mRNA skin cancer vaccine developed by Moderna and Merck has been shown to reduce melanoma death and recurrence by 42%.

HealthcareTechnologyOct 26, 2026score 0.272 posts · 0 replies across 2 instances
The thread discusses a breakthrough in mRNA cancer vaccine research by Moderna and Merck, reporting a 42% reduction in melanoma death and recurrence. The posts reference a news article and a discussion on a tech forum, highlighting the potential impact of this medical advancement.

Claims

The mRNA skin cancer vaccine developed by Moderna and Merck has been shown to reduce melanoma death and recurrence by 42%.
Parent: HealthcareEntity: mRNA cancer vaccineSub-entity: Moderna and MerckImpact: positiveDate: Oct 26, 2026Target: Effectiveness of the mRNA skin cancer vaccine

Source posts

@[email protected]
Link Post: Moderna and Merck say their mRNA skin cancer vaccine cut death, recurrence by 42% https://arstechnica.com/health/2026/10/personalized-mrna-cancer-vaccine-cut-melanoma-death-recurrence-by-42/
0 boosts · 0 favs · 0 replies · Oct 26, 2026
@[email protected]
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% https://arstechnica.com/health/2026/10/personalized-mrna-cancer-vaccine-cut-melanoma-death-recurrence-by-42/ https://news.ycombinator.com/item?id=50235217
0 boosts · 0 favs · 0 replies · Oct 26, 2026